NCT04569916

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

An Exploratory Study to Evaluate Radiotherapy Combined With Irinotecan Liposome and Apatinib Followed by PD-1 Antibody and Apatinib for the Treatment of Advanced Solid Tumors That Failed Standard Treatments

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

Detailed description

This is a prospective, single-arm, observational study. After the subjects meet the inclusive and exclusive criteria, then they will receive radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
RADIATION	radiotherapy	radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
DRUG	irinotecan liposome	radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
DRUG	apatinib	radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
DRUG	PD-1 antibody	radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Timeline

• Start date: 2020-09-01
• Primary completion: 2023-02-01
• Completion: 2023-05-01
• First posted: 2020-09-30
• Last updated: 2020-09-30

Locations

1 site across 1 country: China